A framework provided an outline toward the proper evaluation of potential screening strategies

Journal of Clinical Epidemiology

Volumn 66, Issue 6, 2013, Pages 639-647

  Adriaensen, Wim J ^a   Matheï, Cathy ^a   Buntinx, Frank J ^a,b   Arbyn, Marc ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cancer screening; Cervical cancer; Framework; Harm benefit; Screening evaluation; Screening strategy

Indexed keywords

CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CLINICAL PATHWAY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE DURATION; HUMAN; LONGITUDINAL STUDY; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; POPULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EVALUATION STUDIES AS TOPIC; FEMALE; GUIDELINES AS TOPIC; HEALTH IMPACT ASSESSMENT; HUMANS; MASS SCREENING; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84876930688     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2012.09.018     Document Type: Review

References (42)

1. Wilson J, Jungner G. Principles and practice of screening for disease. WHO public health pap. 1968;34. Available at: http://www.who.int/bulletin/ volumes/86/4/07-050112bp.pdf.
2. L.F. Dans, M.A. Silvestre, and A.L. Dans Trade-off between benefit and harm is crucial in health screening recommendations. Part I: general principles J Clin Epidemiol 64 2011 231 239
3. R. Harris, G.F. Sawaya, V.A. Moyer, and N. Calonge Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive Services Task Force Epidemiol Rev 33 2011 20 35
4. M.A. Silvestre, L.F. Dans, and A.L. Dans Trade-off between benefit and harm is crucial in health screening recommendations. Part II: evidence summaries J Clin Epidemiol 64 2011 240 249
5. Health Council of the Netherlands Population screening for cervical cancer 2011 Health Council of the Netherlands The Hague
6. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, and A. Del Mistro Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Lancet Oncol 11 2010 249 257
7. Cervix Cancer Screening/IARC working group on the evaluation of cancer-preventive strategies 2004 IARCPress Lyon
8. M. Arbyn, X. Castellsaqué, S. de Sanjosé, L. Bruni, M. Saraiya, and F. Bray Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2011 2675 2686
9. G.J. Van Oortmarssen, and J.D. Habbema Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer Br J Cancer 64 1991 559 565
10. M. Hakama Implications of screening on the biology of cervical cancer Nowotwory 36 1986 1 5
11. M. Zwahlen, N. Low, B. Borisch, M. Egger, N. Künzli, and R. Obrist Population-based screening - the difficulty of how to do more good than harm and how to achieve it Swiss Med Wkly 140 2010 1 11
12. G. Koliopoulos, M. Arbyn, P. Martin-Hirsch, M. Kyrgiou, W. Prendiville, and E. Paraskevaidis Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies Gynecol Oncol 104 2007 232 246
13. M. Arbyn, G. Ronco, J. Cuzick, N. Wentzensen, and P.E. Castle How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 125 2009 2489 2496
14. P. Gøtzsche, and M. Nielsen Screening for breast cancer with mammography Cochrane Database Syst Rev 19 2011 CD001877
15. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, and N. Segnan European guidelines for quality sssurance in cervical cancer screening. Second edition - summary document Ann Oncol 21 2010 448 458
16. P. Holowaty, A.B. Miller, T. Rohan, and T. To Natural history of dysplasia of the uterine cervix J Natl Cancer Inst 91 1999 252 258
17. M. Kyrgiou, G. Koliopoulos, P. Martin-Hirsch, M. Arbyn, W. Prendiville, and E. Paraskevaidis Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis Lancet 367 2006 489 498
18. M. Arbyn, M. Kyrgiou, C. Simoens, A.O. Raifu, G. Koliopoulos, and P. Martin-Hirsch Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis BMJ 337 sep18 1 2008 a1284-[a]
19. M. Arbyn, G. Ronco, C.J.L.M. Meijer, and P. Naucle Trials comparing cytology with human papillomavirus screening Lancet Oncol 10 2009 935 936
20. P.M. Bossuyt, J.B. Reitsma, D.E. Bruns, C.A. Gatsonis, P.P. Glasziou, and L.M. Irwig Towards complete and accurate reporting of studies of diagnostic accuracy - the STARD initiative BMJ 326 2003 41 44
21. A. Schatzkin, R.J. Connor, P.R. Taylor, and B. Bunnag Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer Am J Epidemiol 125 1987 672 678
22. R.G. Pretorius, W.H. Zhang, J.L. Belinson, M.N. Huang, L.Y. Wu, and X. Zhang Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse Am J Obstet Gynecol 191 2004 430 434
23. J. Jeronimo, and M. Schiffman Colposcopy at a crossroads Am J Obstet Gynecol 195 2006 349 353
24. A. Van den Bruel, I. Cleemput, B. Aertgeerts, D. Ramaekers, and F. Buntinx The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed J Clin Epidemiol 60 2007 1116 1122
25. R.B. Haynes, and J.J. You The architecture of diagnostic research J.A. Knottnerus, F. Buntinx, The evidence base of clinical diagnosis: theory and methods of diagnostic research 2th ed. 2009 John Wiley & Sons Ltd.; BMJ Books West Sussex, UK pp. 20-41
26. J.G. Lijmer, and P.M. Bossuyt Diagnostic testing and prognosis: the randomized controlled trail in test evaluation research F.B. JA Knottnerus, The evidence base of clinical diagnosis: theory and methods of diagnostic research 2th ed. 2009 BMJ Books 63 83
27. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt, and J.D. Potter Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
28. M. Arbyn, E. Van Veen, K. Andersson, J. Bogers, G. Boulet, and C. Bergeron Cervical cytology biobanking in Europe Int J Biol Markers 25 2010 117 125
29. H. Schünemann, A. Oxman, J. Brozek, P. Glasziou, R. Jaeschke, and G. Vist Grading quality of evidence and strength of recommendations for diagnostic tests and strategies BMJ 336 2008 1106 1110
30. M. Arbyn, P. Sasieni, C.J. Meijer, C. Clavel, G. Koliopoulos, and J. Dillner Chapter 9: clinical applications of HPV testing: a summary of meta-analyses Vaccine 24 Suppl 3 2006 S3/78-89
31. M. Arbyn, F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch, and J. Dillner Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia J Natl Cancer Inst 96 2004 280 293
32. L. Gaffikin, J. McGrath, M. Arbyn, and P.D. Blumenthal Avoiding verification bias in screening test evaluation in resource poor settings: a case study from Zimbabwe Clin Trials 5 2008 496 503
33. F. Buntinx, and M. Brouwers Relation between sampling device and detection of abnormality in cervical smears: a meta-analysis of randomised and quasi-randomised studies BMJ 313 1996 1285 1290
34. P. Martin-Hirsch, R. Lilford, G. Jarvis, and H.C. Kitchener Efficacy of cervical-smear collection devices: a systematic review and meta-analysis The Lancet 354 1999 1763 1770
35. M. Arbyn, C. Bergeron, P. Klinkhamer, P. Martin-Hirsch, A. Siebers, and J. Bulten Liquid compared with conventional cervical cytology: a systematic review and meta-analysis Obstet Gynecol 111 2008 167 177
36. A. Siebers, P. Klinkhamer, J. Grefte, L. Massuger, J. Vedder, and A. Beijers-Broos Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial JAMA 302 2009 1757 1764
37. P. Davies, M. Arbyn, J. Dillner, H.C. Kitchener, C.J. Meijer, and G. Ronco A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening Int J Cancer 118 2006 791 796 [Review]
38. A. Anttila, M. Hakama, L. Kotaniemi-Talonen, and P. Nieminen Alternative technologies in cervical cancer screening: a randomised evaluation trial BMC Public Health 6 2006 252
39. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, and N. Segnan European guidelines for quality assurance in cervical cancer screening Second edition - Summary Document. Ann Oncol 21 2010 448 458
40. M. van Ballegooijen, M.E. van den Akker-van Marle, J. Patnick, E. Lynge, M. Arbyn, and A. Anttila Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness Eur J Cancer 36 2000 2177 2188
41. M. van Ballegooijen, M.E. van den Akker-van Marie, P.G. Warmerdam, C.J.L.M. Meijer, J.M.M. Walboomers, and J.D. Habbema Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness Br J Cancer 76 1997 651 657
42. M.E. van den Akker-van Marle, M. van Ballegooijen, and J.D. Habbema Low risk of cervical cancer during a long period after negative screening in the Netherlands Br J Cancer 88 2003 1054 1057